Trial Questions Role of Dual Immunotherapy in First-Line NSCLC

Published Date: 26 Aug 2024

In Japanese trial, nivolumab-ipilimumab didn't improve OS versus pembrolizumab, had more toxicity

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Trial Questions Role of Dual Immunotherapy in First-Line NSCLC

2.

The Early Progression of Prostate Cancer Is Not Stopped by Metformin.

3.

Three Cycles of Chemo Noninferior to Six for Rare Childhood Eye Cancer

4.

New imaging guidelines for head and neck cancers, a step toward practice change

5.

Even a few mutated cells can significantly impact how blood cancers develop, study finds


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot